Vaxcyte, Inc.
PCVXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. At a $9.10B market cap, Vaxcyte, Inc. ranks as a mid-cap company within healthcare. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Market Cap
$9.10B
Beta
1.22
P/E (TTM)
—
P/E (Fwd)
-8.47
EPS (TTM)
$-7.63
EPS (Fwd)
$-7.22
ROE
-36.5%
ROA
-22.6%
Cash
$1.49B
Total Debt
$115.4M
Free CF
-$485.8M
52W Change
86.9%
Annual Financials
Cash vs Debt
Where PCVX stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, PCVX finished 8.45% above its 150-day moving average ($56.07) and 12.92% above its 200-day moving average ($53.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PCVX overbought or oversold?
At the September 2, 2026 close, PCVX's RSI(14) was 53.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $1.49B in cash and $115.4M in debt, PCVX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$485.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -36.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, PCVX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PCVX.